Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06232044 · ClinicalTrials.gov registry record · Phase 1
Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma
A Phase 1 study, sponsored by Alliance for Clinical Trials in Oncology.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 88
- Enrollment target
NCT06232044 is a Phase 1 study that is actively recruiting participants, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 88 participants.
The verdict
NCT06232044, a Phase 1 study, is actively recruiting participants, sponsored by Alliance for Clinical Trials in Oncology.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 88 participants
- Enrollment target
Study Summary
This phase I/II trial tests the safety, side effects, best dose, and effectiveness of iberdomide in combination with belantamab mafodotin and dexamethasone in treating patients with multiple myeloma (MM) that has come back after a period of improvement (relapsed) or that does not respond to treatment (refractory). Multiple myeloma is a cancer that affects white blood cells called plasma cells, which are made in the bone marrow and are part of the immune system. Multiple myeloma cells have a protein on their surface called B-cell maturation antigen (BCMA) that allows the cancer cells to survive and grow. Immunotherapy with iberdomide, may induce changes in body's immune system and may interfere with the ability of cancer cells to grow and spread. Belantamab mafodotin has been designed to attach to the BCMA protein, which may cause the myeloma cell to become damaged and die. Dexamethasone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs. Iberdomide plus belantamab mafodotin may help slow or stop the growth of cancer in patients with multiple myeloma.
Interventions
- PROCEDURE Computed Tomography
- DRUG Dexamethasone
- DRUG Iberdomide
- PROCEDURE Echocardiography
- BIOLOGICAL Belantamab Mafodotin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2025-04-23 |
| Est. Completion | 2030-08-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06232044
The ClinicalTrials.gov registry entry for NCT06232044 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 88 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Computed Tomography is the first listed.
NCT06232044 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06232044 about?
NCT06232044 is a clinical study titled "Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma". This phase I/II trial tests the safety, side effects, best dose, and effectiveness of iberdomide in combination with belantamab mafodotin and dexamethasone in treating patients with multiple myeloma (MM) that has come back after a period of improvement (relapsed) or that does not respond to treatmen...
What is the current status of trial NCT06232044?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 88 participants. The study started on 2025-04-23. Estimated completion is 2030-08-01.
What interventions are being tested in trial NCT06232044?
The interventions under investigation include: Computed Tomography (PROCEDURE), Dexamethasone (DRUG), Iberdomide (DRUG), Echocardiography (PROCEDURE), Belantamab Mafodotin (BIOLOGICAL).
Who is sponsoring clinical trial NCT06232044?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.